Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Lifecore Biomedical Q3 revenue falls 18.6% to $25.3 million; net loss $40.1 million

Negative Impact 4 of 5 earnings Written later

Lifecore Biomedical reported third-quarter 2026 revenue of $25.3 million, down 18.6% from $31.1 million a year earlier, and a net loss of $40.1 million, or $1.08 per diluted share, compared with a $10.0 million loss, or $0.29 per share, in the prior-year quarter. The filing attributes much of the larger loss to a $31.3 million change in fair value of a related-party debt derivative liability, while adjusted EBITDA rose to $4.0 million, which matters to shareholders because revenue and reported profit both moved against them.

Key points

  • Q3 2026 revenue was $25.3 million vs. $31.1 million; nine-month revenue was $82.7 million vs. $105.7 million.
  • Q3 2026 net loss was $40.1 million, or $1.08 per diluted share, vs. a $10.0 million loss, or $0.29 per share, a year earlier.
  • Q3 change in fair value of debt derivative liability, related party, was a $31.3 million charge; Q3 adjusted EBITDA was $4.0 million vs. $3.1 million.
  • Liquidity was approximately $38.0 million at September 30, 2026, including $23.0 million in cash and $15.0 million of revolving credit availability.

The filing

CompanyLIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:13 AM ET
Accession number0001005286-26-000045

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.